Anuh Pharma Q3: Profit Surges QoQ, But YoY Earnings Dip; USFDA Cleared

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAditi Singh|Published at:
Anuh Pharma Q3: Profit Surges QoQ, But YoY Earnings Dip; USFDA Cleared
Overview

Anuh Pharma reported a robust Q3 FY26 with revenue up 6.08% QoQ to ₹197.18 Cr, and PAT soaring 76.70% QoQ to ₹13.45 Cr, driven by margin expansion. However, for the nine-month period, revenue grew 22.91% YoY to ₹569.54 Cr, while EBITDA and PAT saw declines of 5.66% and 15.85% respectively. The company's USFDA inspection concluded successfully with zero observations. Management guides for 15-16% annual growth and margin improvement.

📉 The Financial Deep Dive

Anuh Pharma Limited has unveiled its Q3 FY26 investor presentation, showcasing a significant quarter-on-quarter recovery while presenting a mixed year-on-year performance.

The Numbers:

  • Q3 FY26 vs Q2 FY26: Operating Revenue climbed 6.08% QoQ to ₹197.18 Cr. EBITDA saw a substantial jump of 62.63% QoQ to ₹20.91 Cr, propelling the EBITDA margin from approximately 6.9% to 10.6%. Profit After Tax (PAT) surged 76.70% QoQ to ₹13.45 Cr, with Earnings Per Share (EPS) mirroring this trend, up 76.32% QoQ to ₹1.34.
  • 9M FY26 vs 9M FY25: On a year-on-year basis for the nine-month period, Operating Revenue demonstrated strong growth, increasing 22.91% to ₹569.54 Cr. However, this top-line growth did not translate to the bottom line. EBITDA declined 5.66% YoY to ₹47.45 Cr, and PAT fell 15.85% YoY to ₹29.36 Cr. Correspondingly, the EBITDA margin compressed from approximately 10.8% in 9M FY25 to 8.3% in 9M FY26.

The Quality:
The quarter-on-quarter surge in profitability and margins is largely attributable to improved operational efficiencies and a significant increase in 'Other Income,' which rose by 319.99% QoQ to ₹4.11 Cr. Depreciation also saw a YoY increase of 40.04% for the nine-month period, reaching ₹8.38 Cr, potentially reflecting capital expenditure on new assets.

The company maintains a robust balance sheet, with a very low Debt to Equity ratio reported at 0.03 in FY24-25, indicating minimal leverage.

🚩 Risks & Outlook

The primary concern highlighted by the results is the year-on-year decline in EBITDA and PAT for the nine-month period, indicating potential headwinds impacting profitability despite revenue growth. This YoY margin compression warrants close monitoring.

However, the management has articulated a clear growth strategy focused on market expansion, new product introductions, and exploring inorganic growth. A key strategic thrust is innovation in complex chemistry products, particularly lifestyle drugs targeting diabetes, hypertension, and obesity. The company has also successfully completed its USFDA inspection in February 2026 with zero observations, a significant operational and regulatory achievement.

Anuh Pharma anticipates a steady annual growth rate of 15-16% and expects continued margin improvement in the coming quarters, driven by capacity expansion, higher utilization, and ongoing operational efficiencies. Investors will be watching to see if the company can translate its QoQ performance and strategic initiatives into sustained YoY profit growth.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.